Home - Vector Biopharma

ABOUT US

Vector BioPharma is a biopharmaceutical company aiming to transform the safety, efficacy, and specificity of drug delivery, to improve treatments for patients. Incorporating cutting-edge platform technologies, from world-class academic research at the University of Zürich, Vector BioPharma uses engineered virus-like particles to achieve cell- and tissue-specific delivery, and tunable expression of genes and regulators with unprecedented precision.

Our Mission

We develop next-generation therapeutics using our proprietary platform that delivers the right gene to the right place at the right time with unparalleled precision and versatility.

TECHNOLOGY

Vector BioPharma’s cutting-edge gene precision delivery technology will transform the safety, efficacy, and specificity of biologics and cell therapies.

Our Shielded, Retargeted Adenovirus-based virus-like particle (SHREAD) platform utilizes a high capacity non-viral particle combined with exogenous, high-avidity adapter proteins to redirect delivery of DNA encoding therapeutics to defined biomarkers on the target cell or tissue, in a highly controlled manner.

This allows for the local production of highly potent drugs with greatly reduced risk of systemic toxicities and opens the door for multiple applications in gene-based medicines.

SELECTED PUBLICATIONS

Freitag et al. Modular Adapters Utilizing Binders of Different Molecular Types Expand Cell-Targeting Options for Adenovirus Gene Delivery Bioconj Chem (2022)

Kirchhammer et al. NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity. Sci Transl Med (2022)

Smith SN et al. The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody. Proc National Acad Sci USA (2021)

Brücher D et al. iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy. Mol Ther Methods Clin Dev (2021)

Schmid M et al. Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control. Nat Comm (2018)

Dreier B et al. Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters. Proc National Acad Sci USA (2013)

PARTNERING

Vector BioPharma is a pharmaceutical company developing its own therapeutic products. The Company’s proprietary delivery technology is available to license by innovative companies with new modalities.

We are looking to partner with pioneers in the fields of immuno-oncology, cell therapies, precision medicine, and academic researchers to revolutionize gene delivery.

CURRENT PARTNERS

University of Zürich

Ridgeline Discovery

INVESTORS

Vector BioPharma will commercialize its technology via the development of therapeutics and is initially focused on immuno-oncology. The company’s SHREAD technology can be used to deliver genes and gene regulators to facilitate the use of next-generation treatment modalities working with DNA, including in-situ expression of immune checkpoint inhibitors and CAR T cell therapies.

Following a successful Series A round in 2021, Vector Biopharma will continue to invest in technology development. We welcome inquiries from investors for series A extension as well as a future Series B investment round.

CURRENT INVESTORS

Versant Ventures

CAREERS

Vector BioPharma values diversity and inclusion and is committed to supporting its team’s personal and career development. If you’d like to find out more about career opportunities at Vector BioPharma, access our current vacancies through our partner’s hiring portal.

LOCATION

Founded in 2021, Vector BioPharma is headquartered in Basel, Switzerland. Situated at the very heart of Europe, bordering France and Germany, Basel boasts diversity, great quality of life and one of the largest pools of pharma talent.